Navigation Links
Boston Scientific to Participate in Merrill Lynch Conference
Date:1/30/2008

NATICK, Mass., Jan. 30 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference, which is being held February 5-7 in New York City.

Paul LaViolette, Chief Operating Officer, will make a 40-minute presentation on Wednesday, February 6, beginning at approximately 10:20 a.m. E.T. Sam Leno, Executive Vice President and Chief Financial Officer will join Mr. LaViolette in a question and answer session.

A live webcast of Mr. LaViolette's remarks and the question and answer session will be available to all interested parties at Boston Scientific's website at http://www.bostonscientific.com. Please visit the website for details on how to access the webcast. To ensure a timely connection to the webcast it is recommended that users register at least 15 minutes before the webcast begins.

This webcast is being hosted by Merrill Lynch. The replay will be archived and available in the Investor Relations site at http://www.bostonscientific.com.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Dan Brennan

508-650-8538 (office)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
2. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
3. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
4. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
5. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
6. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
7. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
8. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
9. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Genzyme Begins Major Expansion of Boston Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is ... the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there ... therapeutic antibodies. , To meet this demand, the team at SCIEX has ...
(Date:3/22/2017)... ... March 21, 2017 , ... Aqua Design Innovations ... goal and raising over $30,000 in the first 40 minutes of crowdfunding. EcoQube ... herbs fast, easy, and affordably, anywhere. , “Simply add fertilized water and in ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... Quantum peristaltic pump with patented ReNu single-use (SU) cartridge technology. Engineered by ... high-pressure feed pumps in SU tangential flow filtration (TFF), virus filtration (VF) ...
(Date:3/22/2017)... WI (PRWEB) , ... March 22, 2017 , ... The ... scientific research agencies as outlined in the Administration’s recently published fiscal year 2018 budget ... the National Institutes of Health (NIH) by $5.8 billion or roughly 20% of its ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
Breaking Biology News(10 mins):